Join the Fulphila group to help and get support from people like you.
Fulphila News
FDA Approves Fylnetra (pegfilgrastim-pbbk), a Biosimilar to Neulasta
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- May 27, 2022 – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has appr...
FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta
REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved Udenyca...
FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta
REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved Udenyca...
FDA Approves Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 4, 2018 /PRNewswire/ – Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food...
Further information
Related condition support groups
Neutropenia Associated with Chemotherapy